Indu Javeri, Author at CuriRx, Inc.

CuriRx Launches the Advanced Bioprocessing and Analytical Center to Support Biotherapeutic Drug Developers

WILMINGTON, Mass., Jan. 26, 2022 /PRNewswire/ — CuriRx, Inc., a leading contract development and manufacturing organization (CDMO), announced today the launch of the Advanced Bioprocessing and […]

November 9: Complimentary CuriLytics™ Lunch & Learn

Join CuriRx for a complimentary Lunch & Learn! CuriLytics™: De-risking CMC characterization by using high resolution mass spectrometry Date: Tuesday, November 9th Time: 12:00-1:00pm Place: MassBio […]

CuriRx Launches CuriLytics™ Platform to Provide CMC Analytical Services to Support Complex Biotherapeutic Development Using High Resolution Mass Spectrometry

WILMINGTON, Mass., Sept. 21, 2021 /PRNewswire/ CuriRx, Inc., a leading contract research (CRO) and product development organization, announced today the launch of their new CuriLytics™ platform with […]

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration

by Vaneet K. Sharma 1,†OrcID,Bijay Misra 2,†,Kevin T. McManus 3,Sreenivas Avula 1,Kaliappanadar Nellaiappan 2OrcID,Marina Caskey 4,Jill Horowitz 4,Michel C. Nussenzweig 4,5,Michael S. Seaman 3,Indu Javeri 2 […]